WASHINGTON Japan's Eisai Co Ltd (4523.T) won a
legal fight on Monday with Israel's Teva Pharmaceutical
Industries Ltd TEVA.O, the world's largest generic drug
company, over acid reflux drug Aciphex.
The U.S. Court of the Appeals for the Federal Circuit
upheld a summary judgment by a New York court that found the
Eisai patent for Aciphex was valid.
That court also ruled after a bench trial that Teva and
Indian drug maker Dr. Reddy's Laboratories Ltd (REDY.BO)(RDY.N)
infringed on Eisai's patent based on the fact that each of the
two filed an abbreviated new drug application, or ANDA, seeking
to manufacture a generic version of Aciphex.
The case also affects Mylan Inc MYL.N, which also filed
an ANDA on the drug. Mylan had agreed to be bound by the
outcome of Eisai's lawsuit against Teva and Dr. Reddy's.
(Reporting by Diane Bartz; Editing by Andre Grenon)